A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

ClinicalTrials.gov ID: NCT04019561

Public ClinicalTrials.gov record NCT04019561. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)

Study identification

NCT ID: NCT04019561
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 74 participants

Conditions and interventions

Conditions

Interventions

MEDI0382 high dose Drug
Placebo for MEDI0382 high dose Drug
MEDI0382 low dose Drug
Placebo for MEDI0382 low dose Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 101 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 22, 2019
Primary completion: May 5, 2021
Completion: May 5, 2021
Last update posted: Jan 16, 2023

2019 – 2021

United States locations

U.S. sites: 26
U.S. states: 10
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85712	—
Research Site	Canoga Park	California	91303	—
Research Site	Chula Vista	California	91911	—
Research Site	Coronado	California	92118	—
Research Site	La Jolla	California	92093	—
Research Site	Lincoln	California	95648	—
Research Site	Los Angeles	California	90057	—
Research Site	Montclair	California	91763	—
Research Site	Torrance	California	90505	—
Research Site	Westminster	California	92683	—
Research Site	Doral	Florida	33166	—
Research Site	Hialeah	Florida	33016	—
Research Site	Miami	Florida	33125	—
Research Site	Miami	Florida	33189	—
Research Site	Palmetto Bay	Florida	33157	—
Research Site	Marrero	Louisiana	70072	—
Research Site	Las Vegas	Nevada	89104	—
Research Site	Las Vegas	Nevada	89109	—
Research Site	Durham	North Carolina	27705	—
Research Site	Blue Ash	Ohio	45242	—
Research Site	Chattanooga	Tennessee	37421	—
Research Site	Houston	Texas	77002	—
Research Site	Houston	Texas	77084	—
Research Site	San Antonio	Texas	78215	—
Research Site	San Antonio	Texas	78229	—
Research Site	Richmond	Virginia	23219	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04019561, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 16, 2023 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04019561 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →